Skip to main content

Inovio Pharmaceuticals, Inc.

corporate_fare Company Profile

Inovio Pharmaceuticals, Inc.

INO·NASDAQ·Life Sciences·CIK 0001055726

Inovio Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes DNA medicines. These medicines are designed to treat and protect people from diseases linked to human papillomavirus (HPV), various cancers, and infectious diseases. The company's DNA medicines platform utilizes SynCon technology to engineer specific plasmid DNA plasmids, along with CELLECTRA smart devices for delivering these DNA plasmids. Inovio's primary product candidate is INO-3107, which is in a Phase 1/2 trial for HPV-related recurrent respiratory papillomatosis. Other products in its development pipeline include VGX-3100 for HPV-related cervical high-grade squamous intraepithelial lesions, INO-3112 for HPV-related Oropharyngeal squamous cell carcinoma (currently in a Phase 2 trial), and INO-5401 for glioblastoma multiforme (also in a Phase 2 trial). Additionally, the pipeline features INO-4201 for Ebola Virus Disease (in a Phase 1b trial), INO-4800 for COVID-19 (in a Phase 2/3 trial), and INO-6160 for human immunodeficiency virus (in a Phase 1 trial). The company collaborates with various partners, including ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. Inovio Pharmaceuticals, Inc. was founded in 1983 and is based in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for INO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for INO spans 10-Q, 8-K, 424B5, FWP.

Recent high-impact activity:

  • Inovio Posts $49.2M Q3 Loss as First Commercial Launch of VOCERYQ Takes Shape
  • Inovio Q3: $49.2M Loss, $48.4M Cash, Going Concern Pushed to Late Q4 2027
  • Inovio Finalizes $80.5M Net Raise as Underwriters Take Full Option
  • Inovio Prices $75M Offering at $1.05, a 28% Discount to Last Sale, Days After First FDA Approval
  • Inovio Prices $75M Offering at $1.05, a 15% Discount to Thursday's Close

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$65.34K
Net Income
-$84.95M
Diluted EPS
-$1.81
Op. Cash Flow
-$88.63M
Free Cash Flow
-$88.92M
Operating Income
-$86.82M
Cash & Equivalents
$44.27M
Debt / Equity
0.00×
Net Margin
-1300.00×
Shares Outstanding
69M sh
Source: 10-K · filed 2026-03-12 · accession 0001055726-26-000008

Short Interest & Short Volume

1.82 days to cover

FINRA reported short interest of 22,100,943 shares in INO as of the October 30, 2026 settlement, a 3.7% increase from the prior period — about 1.8 days to cover at its recent average daily volume. On November 20, 2026, 38.0% of INO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)22,100,943 shares as of October 30, 2026
Change vs prior period▲ 3.7%
Days to cover1.82 at avg daily volume of 12,147,378
Daily short volume (FINRA facilities)38.0% of 4,279,694 shares on November 20, 2026
5-day average short volume35.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for INO, detected from its recent SEC filings · based on capital-structure filings through 2026-11-06.

2 recent capital raisesATM program1 shelf registration

Offering Priced at $1.05 Per Share · Net Proceeds of About $70M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with I →
$1.84 +4.55% today
52-week range · as of 2026-11-10 $0.5632 – $2.72
Market cap
$329.66M
Volume
7.9M (0.4× avg)
3-mo avg 20.6M
Live data · 2026-11-22 04:04 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed INO - Latest Insights

INO
Nov 10, 2026, 4:05 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $1.84 info
Change: +$0.380 (+26%) info
Market Cap: $329.66M info
INO
Nov 10, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $1.84 info
Change: +$0.370 (+25%) info
Market Cap: $329.66M info
INO
Nov 09, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.37
Real-time Price: $1.84 info
Change: +$0.470 (+34%) info
Market Cap: $329.66M info
INO
Nov 06, 2026, 4:30 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.21
Real-time Price: $1.84 info
Change: +$0.630 (+52%) info
Market Cap: $329.66M info
INO
Nov 05, 2026, 11:19 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $1.84 info
Change: +$0.6106 (+50%) info
Market Cap: $329.66M info
INO
Nov 05, 2026, 7:46 PM EST
Filing Type: FWP
Importance Score:
7
Price at Filing: $1.15
Real-time Price: $1.84 info
Change: +$0.6892 (+60%) info
Market Cap: $329.66M info
INO
Nov 05, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.24
Real-time Price: $1.84 info
Change: +$0.600 (+48%) info
Market Cap: $329.66M info
INO
Nov 05, 2026, 4:10 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $1.84 info
Change: +$0.640 (+53%) info
Market Cap: $329.66M info
INO
Nov 05, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.44
Real-time Price: $1.84 info
Change: +$0.405 (+28%) info
Market Cap: $329.66M info
INO
Nov 02, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.00
Real-time Price: $1.84 info
Change: -$0.160 (-8%) info
Market Cap: $329.66M info
INO
Oct 30, 2026, 5:35 PM EDT
Source: Seeking Alpha
Importance Score:
9
Price at Filing: $2.30
Real-time Price: $1.84 info
Change: -$0.460 (-20%) info
Market Cap: $329.66M info
INO
Oct 30, 2026, 4:40 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.32
Real-time Price: $1.84 info
Change: +$0.5201 (+39%) info
Market Cap: $329.66M info
INO
Oct 20, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.02
Real-time Price: $1.84 info
Change: +$0.820 (+80%) info
Market Cap: $329.66M info
INO
Aug 12, 2026, 4:14 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.7789
Real-time Price: $1.84 info
Change: +$1.06 (+136%) info
Market Cap: $329.66M info
INO
Aug 12, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.780
Real-time Price: $1.84 info
Change: +$1.06 (+136%) info
Market Cap: $329.66M info
INO
Aug 12, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.770
Real-time Price: $1.84 info
Change: +$1.07 (+139%) info
Market Cap: $329.66M info
INO
Jul 29, 2026, 8:55 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.8195
Real-time Price: $1.84 info
Change: +$1.02 (+125%) info
Market Cap: $329.66M info
INO
Jul 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.825
Real-time Price: $1.84 info
Change: +$1.02 (+123%) info
Market Cap: $329.66M info
INO
Jul 29, 2026, 4:01 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.825
Real-time Price: $1.84 info
Change: +$1.02 (+123%) info
Market Cap: $329.66M info
INO
Jul 29, 2026, 4:01 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $0.880
Real-time Price: $1.84 info
Change: +$0.960 (+109%) info
Market Cap: $329.66M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets